RxDoctor Payments DataLook up a doctor →

Joseph Habibi, MD

Urology · Williamsburg, VANPI 1912227471

Payments from drug & device makers

$20,856in general payments, 2019–2025

Across 548 payments — averaging $38.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$9K
  • AbbVie$1K
  • Medtronic$980
  • Pfizer$753
  • Sumitomo Pharma America, Inc.$739
  • Johnson & Johnson$722
  • plus $7K from 52 others

What the payments were for

  • Food & beverage$11,60656%
  • Education$9,25044%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,856 in reported general payments places this provider in the 85th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$584,721
Medicare patients
1,478
Services billed
13,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide13$174,247
MyrbetriqMirabegron104$117,393
GemtesaVibegron75$70,579
Tamsulosin Hcl665$11,124
Finasteride373$6,142
Trospium Chloride51$4,458
Methenamine Hippurate44$4,222
Potassium Citrate ErPotassium Citrate31$3,858
Solifenacin Succinate40$2,710
Testosterone12$2,469
Alfuzosin Hcl ErAlfuzosin Hcl113$2,468
Oxybutynin Chloride ErOxybutynin Chloride94$2,108
Testosterone Cypionate28$1,338
Desmopressin Acetate28$1,251
Dutasteride26$739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$579$291,640117 claims
Sumitomo Pharma America, Inc.Gemtesa$739$70,57975 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 300 urology providers in Virginia.

Other urology in Williamsburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →